Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Conference Call April 30, 2024 10:00 AM ET
Company Participants
Joe Fletcher – Senior Vice President-Investor Relations
Dave Ricks – Chief Executive Officer
Anat Ashkenazi – Chief Financial Officer
Dan Skovronsky – Chief Scientific Officer and President-Lilly Immunology
Anne White – President-Lilly Neuroscience
Jake Van Naarden – President-Loxo
Patrik Jonsson – President-Lilly Diabetes and Obesity and Lilly USA
Conference Call Participants
Chris Schott – JPMorgan
Mohit Bansal – Wells Fargo
Umer Raffat – Evercore
Seamus Fernandez – Guggenheim
Tim Anderson – Wolfe Research
Terence Flynn – Morgan Stanley
Akash Tewari – Jefferies
Trung Huynh – UBS
Geoff Meacham – Bank of America
Kerry Holford – Berenberg
Steve Scala – TD Cowen
Evan Seigerman – BMO Capital Markets
David Risinger – Leerink Partners
Louise Chen – Cantor
Chris Shibutani – Goldman Sachs
Carter Gould – Barclays
Kripa Devarakonda – Truist Securities
James Shin – Deutsche Bank
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2024 Earnings Call. At this time all participants are in a listen-only mode. Later we will be conducting a question-and-answer session and instructions will be given at that time. [Operator Instructions]
I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.
Joe Fletcher
Thank you, Paul, and good morning everyone. Thank you for joining us for Eli Lilly and Company's Q1 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations. And joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Anat Ashkenazi, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Loxo at Lilly; and Patrik Jonsson, President of Lilly Diabetes and Obesity and Lilly USA. We're also joined by Michaela Irons, Mike Springnether and Lauren Zierki of the IR team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Actual results could differ materially due to several factors, including those listed on Slide 2. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community. It's not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note our commentary will focus on our non-GAAP financial measures.